Infectious Disease Alert – January 1, 2020

January 1, 2020

• Preventing Readmissions and Optimizing Outcomes for Staphylococcus aureus Bacteremia: Still a Long Journey Ahead

  Using a population-based database, investigators found that the rate of readmission within 30 days following hospitalization for S. aureus bacteremia was high (22%) and resulted in high cost to the healthcare system.

  Read more about Preventing Readmissions and Optimizing Outcomes for <i>Staphylococcus aureus</i> Bacteremia: Still a Long Journey Ahead - Infectious Disease Alert – January 1, 2020

• What Is the Risk of Joint Prosthesis Infection Resulting From Bacteremia?

  The risk of periprosthetic joint infection resulting from bacteremia depends on the organism.

  Read more about What Is the Risk of Joint Prosthesis Infection Resulting From Bacteremia? - Infectious Disease Alert – January 1, 2020

• Fulminant Clostridioides difficile Infection: Hold the IV Metronidazole?

  The combination of oral vancomycin and intravenous metronidazole is not superior to vancomycin alone in the treatment of fulminant infection due to Clostridioides difficile.

  Read more about Fulminant Clostridioides difficile Infection: Hold the IV Metronidazole?

• Cefazolin and Ertapenem as Salvage Therapy in Methicillin-Susceptible Staphylococcus aureus Bacteremia

  Cefazolin (CZ) and ertapenem combination therapy was successfully used to salvage 11 cases of persistent methicillin-susceptible Staphylococcus aureus bacteremia. Modest in vitro synergy between CZ and ertapenem was demonstrated on testing of six clinical isolates, but in vivo activity appeared more potent in an animal model than as predicted by in vitro activity.

  Read more about Cefazolin and Ertapenem as Salvage Therapy in Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia - Infectious Disease Alert – January 1, 2020

• Markers and Mechanisms of Chronic Fatigue Following Mononucleosis

  Chronic disabling fatigue affects up to 2% of adolescents and often follows Epstein-Barr virus-related mononucleosis. No clinically significant infectious, immune, neuroendocrine, or autonomic biomarker or pathophysiologic mechanism has been identified to differentiate those with mononucleosis who go on to develop chronic fatigue from those who recover.

  Read more about Markers and Mechanisms of Chronic Fatigue Following Mononucleosis - Infectious Disease Alert – January 1, 2020

• Omeprazole Magnesium, Amoxicillin, and Rifabutin Delayed-Release Capsules (Talicia)

  The FDA has approved a fixed-dose combination, rifabutin-based (RFB) regimen to treat Helicobacter pylori infection.

  Read more about Omeprazole Magnesium, Amoxicillin, and Rifabutin Delayed-Release Capsules (Talicia) - Infectious Disease Alert – January 1, 2020

• Infectious Disease Alert Updates

  Objects of Delusional Infestation; Urine Eosinophils Unreliable; Tecovirimat for Laboratory-Acquired Vaccinia

  Read more about Infectious Disease Alert Updates - Infectious Disease Alert – January 1, 2020